X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (40) 40
dermatology (30) 30
index medicus (29) 29
female (23) 23
male (20) 20
aged (13) 13
lichenoid eruptions - chemically induced (13) 13
middle aged (13) 13
adult (10) 10
drug eruptions - etiology (10) 10
immunotherapy (10) 10
lichenoid eruptions - pathology (10) 10
cancer (9) 9
lichenoid eruptions - drug therapy (9) 9
dermatitis (8) 8
programmed cell death 1 receptor - antagonists & inhibitors (8) 8
antibodies, monoclonal - adverse effects (7) 7
ipilimumab (7) 7
metastatic melanoma (7) 7
nivolumab (7) 7
oncology (7) 7
pathology (7) 7
skin (7) 7
skin - pathology (7) 7
antineoplastic agents - adverse effects (6) 6
drug eruptions - pathology (6) 6
lichenoid reaction (6) 6
planus (6) 6
young adult (6) 6
aged, 80 and over (5) 5
anti-ctla-4 (5) 5
bullous pemphigoid (5) 5
immune checkpoint (5) 5
lichenoid dermatitis (5) 5
medicine & public health (5) 5
melanoma (5) 5
neoplasms - drug therapy (5) 5
pembrolizumab (5) 5
adverse events (4) 4
anti-pd-1 therapy (4) 4
antibodies, monoclonal, humanized - adverse effects (4) 4
antineoplastic agents, immunological - adverse effects (4) 4
apoptosis (4) 4
b7-h1 antigen - antagonists & inhibitors (4) 4
care and treatment (4) 4
chemotherapy (4) 4
complications and side effects (4) 4
dental amalgam - adverse effects (4) 4
dentistry, oral surgery & medicine (4) 4
dermatologic toxicities (4) 4
dermatological toxicities (4) 4
diagnosis (4) 4
eruptions (4) 4
inflammation (4) 4
lichenoid (4) 4
mercury (4) 4
monoclonal antibodies (4) 4
oral lichenoid lesions (4) 4
photosensitivity (4) 4
surgery (4) 4
treatment outcome (4) 4
analysis (3) 3
animals (3) 3
anti-pd-1 (3) 3
anti-pd-l1 (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
cell death (3) 3
chronic myelogenous leukemia (3) 3
chronic myeloid-leukemia (3) 3
disease (3) 3
glucocorticoids - therapeutic use (3) 3
imatinib mesylate (3) 3
immune checkpoint blockade (3) 3
immune-related adverse events (3) 3
immune‐related adverse events (3) 3
lichenoid eruption (3) 3
melanoma - drug therapy (3) 3
mercury - adverse effects (3) 3
mucosa (3) 3
nivolumab therapy (3) 3
paraneoplastic pemphigus (3) 3
patch tests (3) 3
pemphigus (3) 3
pharmacology & pharmacy (3) 3
psoriasis (3) 3
safety (3) 3
skin - drug effects (3) 3
stem-cell transplantation (3) 3
stevens-johnson-syndrome (3) 3
t-cells (3) 3
therapy (3) 3
toxicity (3) 3
vitiligo (3) 3
acantholysis - chemically induced (2) 2
administration, topical (2) 2
adolescent (2) 2
allergic contact dermatitis (2) 2
allergy (2) 2
alopecia - chemically induced (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annales de Dermatologie et de Venereologie, ISSN 0151-9638, 05/2018, Volume 145, Issue 5, pp. 313 - 330
The development of immune checkpoint inhibitors (monoclonal antibodies targeting PD-1/PD-L1 or CTLA-4) represents a significant advance in the treatment of... 
Vitiligo | Anti-PD-1 | Psoriasis | Sarcoidosis | Maculopapular rash | Anti-CTLA-4 | Anti-PD-L1 | Bullous pemphigoid | Sicca syndrome | Lichenoid reaction
Journal Article
Journal of Cutaneous Pathology, ISSN 0303-6987, 10/2018, Volume 45, Issue 10, pp. 764 - 773
Journal Article
JOURNAL OF CUTANEOUS PATHOLOGY, ISSN 0303-6987, 10/2017, Volume 44, Issue 10, pp. 851 - 856
BackgroundImmune checkpoint agents targeting programmed cell death-1 protein (PD1) or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) receptors are... 
PATHOLOGY | lichenoid inflammation | DERMATOLOGY | UNTREATED MELANOMA | METASTATIC MELANOMA | dermatologic toxicities | ANTI-PD-1 THERAPY | PEMBROLIZUMAB | pemphigus | IMMUNE CHECKPOINT BLOCKADE | PARANEOPLASTIC PEMPHIGUS | DISEASE | anti-CTLA-4 | anti-PD1 | OF-THE-LITERATURE | NIVOLUMAB | IPILIMUMAB
Journal Article
Journal of Cutaneous Pathology, ISSN 0303-6987, 09/2019, Volume 46, Issue 9, pp. 627 - 636
Journal Article
Journal Article
12/2013, ISBN 9780470621882, 14
Adverse drug reactions are responsible for 6% of all hospital admissions. Drug reactions can present in a variety of ways, although cutaneous drug eruptions... 
acneiform eruptions | drug‐induced vasculitis | exanthematous eruptions | pustular eruptions | dermatologic reactions | erythroderma | urticarial eruptions | bullous eruptions | lichenoid eruptions
Book Chapter
Journal Article